(Reuters) – Johnson & Johnson
The participant’s illness is being reviewed and evaluated by an independent data and safety monitoring board as well as the company’s clinical and safety physicians, it said https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials in a statement.
Stat News reported the pause earlier in the day citing a document sent to outside researchers running the 60,000-patient clinical trial, which stated that a “pausing rule” had been met, the online system used to enroll patients in the study had been closed and the data and safety monitoring board would be convened.
(Reporting by Ayanti Bera in Bengaluru; Editing by Rashmi Aich)
